UPDATE: Lexicon Pharma (LXRX) Reports Prelim. Update for Zynquista (Sotagliflozin) Type 2 Diabetes Phase 3 Program; Confirms Sanofi (SNY) to Terminate Collaboration
Tweet Send to a Friend
(Updated - July 29, 2019 5:47 AM EDT)Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), received preliminary topline results from Sanofi for three ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
